recurrent glioblastoma pipeline insight

DelveInsight’s, “Recurrent Glioblastoma Pipeline Insight, 2026” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Recurrent Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Recurrent Glioblastoma Understanding

Recurrent Glioblastoma Overview

Recurrent glioblastoma is the return of Glioblastoma, an aggressive and high-grade primary brain tumor, after initial treatment such as surgery, radiation, and chemotherapy. It is one of the most challenging cancers to treat due to its highly invasive nature and tendency to infiltrate surrounding brain tissue. Even after optimal therapy, recurrence is common because microscopic tumor cells often remain undetected. The prognosis for recurrent disease is generally poor, and management focuses on prolonging survival while maintaining quality of life.

The signs and symptoms of recurrent glioblastoma are similar to those seen at initial diagnosis but may be more severe or progressive. Patients commonly experience persistent headaches, seizures, nausea and vomiting due to increased intracranial pressure. Neurological deficits such as weakness, speech difficulties, memory loss, or personality changes may also occur, depending on the tumor’s location. Symptoms often worsen over time as the tumor grows and disrupts normal brain function.
The pathophysiology of recurrent glioblastoma involves rapid tumor cell proliferation, resistance to therapy, and genetic mutations that promote survival and invasion. Tumor cells exhibit abnormal signaling pathways, increased angiogenesis (formation of new blood vessels), and the ability to evade apoptosis (programmed cell death). A key feature is tumor heterogeneity, meaning different populations of cancer cells respond differently to treatment. Additionally, the blood-brain barrier limits the effectiveness of many drugs, contributing to recurrence. Diagnosis of recurrent glioblastoma typically involves imaging studies such as MRI with contrast, which helps identify tumor regrowth and differentiate it from treatment-related changes like radiation necrosis. Advanced imaging techniques and clinical evaluation are often required for accurate assessment. In some cases, a biopsy or repeat surgery may be performed to confirm recurrence. Continuous monitoring is essential for early detection and timely intervention.

Treatment of recurrent glioblastoma is complex and individualized. Options may include repeat surgical resection, re-irradiation, and chemotherapy with agents like Temozolomide or targeted therapies such as Bevacizumab. Supportive care, including anti-epileptic drugs and corticosteroids, is important for symptom control. Emerging approaches like immunotherapy and clinical trials offer potential benefits for some patients. Overall, management focuses on extending survival, controlling symptoms, and improving the patient’s quality of life.

"Recurrent Glioblastoma Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Recurrent Glioblastoma pipeline landscape is provided which includes the disease overview and Recurrent Glioblastoma treatment guidelines. The assessment part of the report embraces, in depth Recurrent Glioblastoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Recurrent Glioblastoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Discover the latest Recurrent Glioblastoma pipeline insights, emerging therapies, and clinical advancements shaping the future of treatment in 2026.

Recurrent Glioblastoma Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Recurrent Glioblastoma R&D. The therapies under development are focused on novel approaches to treat/improve Recurrent Glioblastoma.

Recurrent Glioblastoma Emerging Drugs Analysis

This segment of the Recurrent Glioblastoma report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Recurrent Glioblastoma Emerging Drugs

TLX-101-Tx + Lomustine: Telix Pharmaceuticals (Innovations) Pty Limited

TLX101 is a novel approach that is readily able to pass through the blood-brain barrier, the normal protective barrier that prevents many potential drug candidates from entering the brain. TLX101-Tx, an investigational radiopharmaceutical therapy, in combination with lomustine versus lomustine alone in adult patients with first recurrence of glioblastoma. TLX101-Tx delivers targeted radiation to glioblastoma cells.  The mainstay of treatment for glioblastoma comprises surgical resection, followed by combined radiotherapy and chemotherapy. Despite such treatment, recurrence occurs in almost all patients. TLX101 (131I-IPA) is a candidate for GBM, currently being evaluated in front line and recurrent GBM in the IPAX studies. TLX101 targets L-type amino acid transporter 1 (LAT-1), typically over-expressed in GBM.  The drug is currently in Phase III for the treatment of recurrent glioblastoma. 

BL-B01D1: Sichuan Baili Pharmaceutical Co., Ltd.

BL-B01D1 is the world’s first and only clinical-stage EGFR × HER3 bispecific ADC. EGFR and HER3 are broadly overexpressed in numerous types of epithelial tumors. The bispecific structure of BL-B01D1 is designed to target a wide range of solid tumors and achieve greater enrichment within tumor tissues, thereby enhancing tumor killing activity and reducing on-target off-tumor toxicity. BL-B01D1 is a potentially first-in-class bispecific ADC developed by SystImmune, targeting both EGFR and HER3, which are highly expressed in most epithelial tumors. BL-B01D1 is comprised of SystImmune's proprietary bispecific antibody and linker-payload which contains a stable, cleavable linker and a topoisomerase inhibitor. The drug is currently in Phase II stage of its development for the treatment of recurrent glioblastoma.

VXM01: VAXIMM AG

VXM01, is an oral immunotherapy that activates T-cells against VEGFR2, a key validated protein in the tumor vasculature. By activating this process with VXM01, tumor blood supply is abolished while enabling infiltration of immune cells with broad anti-tumor effects. VXM01 carries the vascular endothelial growth factor receptor-2 (VEGFR2), which is highly overexpressed on the tumor vasculature and on certain cancer cells as the target gene. The active, T-cell-mediated destruction of tumor vasculature cells leads to an increased infiltration of various immune cells into tumor tissue (inflammation). VXM01 has also received orphan designation from the European Commission and from the US Food and Drug Administration (FDA) for the treatment of glioblastoma.

In preclinical studies, a murine analog VXM01 vaccine showed broad anti-tumor activity in different tumor types. This activity was linked to a VEGFR2-specific T-cell response and was accompanied by the destruction of the tumor vasculature and increased immune cell infiltration. Currently the drug is in Phase II stage of its clinical development for the treatment of recurrent glioblastoma. 

A Phase I/II trial evaluating VXM01 in combination with avelumab, a human anti-PD-L1 antibody, for the treatment of glioblastoma is ongoing. The trial is part of a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. 

Collaboration: In May 2017, VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, announced that it had entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany KGaA, Darmstadt, Germany, and Pfizer Inc. to evaluate avelumab*, a human anti-PD-L1 antibody, in combination with VAXIMM’s VXM01. VXM01 is an investigational oral T-cell immunotherapy designed to activate T-cells to attack the tumor vasculature, and, in several tumor types, attack cancer cells directly. Under the terms of the agreement, VAXIMM will be responsible for conducting two open-label Phase I/II trials –one in glioblastoma and one in metastatic colorectal cancer.

Results Update: 

In March 2025, Vaximm AG, a subsidiary of OSR Holdings, Inc. announced final data from the successful conclusion of its open-label Phase IIa clinical trial assessing the safety and tolerability of VXM01, an investigational oral anti-VEGFR-2 vaccine, in combination with avelumab (PD-L1 inhibitor) in patients with recurrent glioblastoma (GBM). The trial was part of a collaboration with Merck KGaA, Darmstadt, Germany.
In May 2020, VAXIMM announced first results from Phase I/II trial in Progressive Glioblastoma with Oral T-cell Immunotherapy VXM01 in Combination with PD-L1 Inhibitor Avelumab which was presented as oral presentation at the 2020 American Society of Clinical Oncology (ASCO) Virtual Meeting.
 
Phase II Results: 

Key results and observations:

The VXM01-avelumab combination therapy was generally well-tolerated, with the majority of safety events being mild to moderate in severity. These safety and tolerability data are in-line with previously reported data on avelumab alone with no additional safety signals for the combination of VXM01 and avelumab.

No serious adverse events (SAEs) were attributed to VXM01, while 9 of 11 (81.8%) were related to the target disease, underscoring the well manageable safety profile of this combination therapy in a frail patient population. 
The non-resected patient cohort showed a 12.0% objective response rate (ORR). 12.0% of these patients showed a partial remission and 4.0% had stable disease. This suggests that, with further investigation, VXM01 in combination with PD-L1 inhibition (e.g. avelumab) could offer meaningful clinical benefit for this challenging patient population. In resected patients, the overall survival (OS) ranged from 2.2 to 46.5 months, highlighting the variability in response and the need for additional studies to determine optimal treatment regimens for specific subgroups of GBM patients.
Despite the small size of this open-label trial (n=25), the observed median time to progression of 2.7 months (95% CI: 2.7 – 2.7, range  0.3 - 22.1 months), and median OS of 11.1 months (95% CI: 8.5 – 16.3, range  3.8- 38.2 months), are encouraging initial results in the context of prognosis for patients with recurrent glioblastoma,  reported to have a median PFS of 1.5 to 6 months and median OS of 2 to 9 months.
Decreased tumor size was observed in responding patients independent of tumor size at baseline, supporting the expectation that VXM01 vaccine treatment may be effective in patients with larger sized tumors as well as patients with early-stage cancer or very small tumors.
Exploratory biomarker investigations identified potential predictive and pharmacodynamic biomarkers of a VXM01-mediated tumor response  

Conclusions: The reported safety and tolerability data, together with early indications for the potential relevance of a VXM01dependent, VEGFR-2 specific immune response in GBM therapy warrant further study. Results provides strong evidence that VXM01, in combination with avelumab is generally well-tolerated in patients with recurrent glioblastoma.

Phase I/II Results: The multicenter, open-label Phase I/II trial (EudraCT #: 2017-003076-31) is designed to evaluate the safety and tolerability of VXM01 in combination with the PD-L1 inhibitor avelumab in 30 patients with recurrent glioblastoma at multiple clinical sites in Europe. Secondary endpoints include objective response rate (ORR), clinical response using immune-response assessment in neuro-oncology (iRANO) criteria and immunological assays. Nine patients treated with VXM01 and avelumab in 2 dose groups had completed the safety run-in phase.

No treatment-related toxicities were observed in the 9 patients treated. Three partial responses according to iRANO criteria with tumor reductions of 58, 81 and 95% to baseline were reported. Two of these patients have been progression free for more than 6 months. Furthermore, significant VEGFR2-specific T-cell responses were measured in several patients, and pre-existing intra-tumoral T-cells were positively associated with the effectiveness of the immunotherapy combination.

CUE-102: Cue Biopharma

CUE-102 is Cue Biopharma’s second clinical drug candidate from the CUE-100 series of interleukin 2 (IL-2)-based biologics. It is designed to activate and expand Wilms’ Tumor 1 (WT1)-specific T cells by presenting the WT1 peptide to the WT1-specific T cell receptor. WT1 is a well-recognized onco-fetal protein known to be over-expressed in a number of cancers, including solid tumors and hematologic malignancies. CUE-102 has demonstrated anti-tumor activity and a favorable tolerability profile with no dose limited toxicities. The drug is currently in Phase I for the treatment of recurrent glioblastoma. 

Further product details are provided in the report……..

Recurrent Glioblastoma Therapeutic Assessment

This segment of the report provides insights about the different Recurrent Glioblastoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Recurrent Glioblastoma Players in Recurrent Glioblastoma

There are approx. 45+ key companies which are developing the therapies for Recurrent Glioblastoma. The companies which have their Recurrent Glioblastoma drug candidates in the most advanced stage, i.e. Phase III include, Telix Pharmaceuticals (Innovations) Pty Limited.

Recurrent Glioblastoma Clinical Trial Phases

DelveInsight’s report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Recurrent Glioblastoma Drug Route of Administration

Recurrent Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

Recurrent Glioblastoma Product Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

Recurrent Glioblastoma Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Recurrent Glioblastoma Clinical Trial Activities

The Recurrent Glioblastoma Pipeline report provides insights into different Recurrent Glioblastoma clinical trials within Phase III, II, I, preclinical and discovery stage. It also analyses Recurrent Glioblastoma therapeutic drugs key players involved in developing key drugs. 

Recurrent Glioblastoma Pipeline Development Activities

The Recurrent Glioblastoma clinical trial analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Recurrent Glioblastoma drugs.

Recurrent Glioblastoma Pipeline Report Insights

• Recurrent Glioblastoma Pipeline Analysis
• Recurrent GlioblastomaTherapeutic Assessment
• Recurrent Glioblastoma Unmet Needs
• Impact of Recurrent Glioblastoma Drugs

Recurrent Glioblastoma Pipeline Report Assessment

• Recurrent Glioblastoma Pipeline Product Profiles
• Recurrent Glioblastoma Therapeutic Assessment
• Recurrent Glioblastoma Pipeline Assessment
• Recurrent Glioblastoma Inactive drugs assessment
• Recurrent Glioblastoma Market Unmet Needs

Discover actionable insights into the Recurrent Glioblastoma market trends, epidemiology trends, and forecast through 2032 to stay ahead in emerging therapies.

Key Questions Answered In The Recurrent Glioblastoma Pipeline Report:

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Recurrent Glioblastoma drugs?
• How many Recurrent Glioblastoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Recurrent Glioblastoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Recurrent Glioblastoma therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Recurrent Glioblastoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Recurrent Glioblastoma Key Companies

• Telix Pharmaceuticals (Innovations) Pty Limited
• Sichuan Baili Pharmaceutical Co., Ltd.
• VAXIMM AG
• Cue Biopharma
• Revolution Medicines, Inc.
• BioNTech SE
• Ascletis Pharmaceuticals Co., Ltd.
• Sichuan Honghe Biotechnology Co., Ltd.
• Shanghai Simnova Biotechnology Co.,Ltd.
• Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
• Beijing Immunochina Medical Science & Technology Co., Ltd.
• BeyondBio Inc.
• Chimeric Therapeutics
• KATMAI Pharmaceuticals
• CNS Pharmaceuticals, Inc.

Recurrent Glioblastoma Key Products

• TLX-101-Tx + Lomustine
• BL-B01D1
• VXM01
• CUE-102
• RMC-5552
• BNT327
• ASC40
• KH617
• SNC109
• BC008-1A
• WL276 CAR-T cells
• BEY1107
• CHM-1101 CAR-T cells
• KTM-101
• Berubicin

Explore comprehensive insights into Recurrent Glioblastoma epidemiology trends, patient population forecasts, and growth opportunities through 2034 for strategic decision-making.